Want to see QTTB full AI Analyst Report?
Total Valuation
Q32 Bio has a market cap or net worth of $466.70M. The enterprise value is $158.19.
Market Cap$466.70M
Enterprise Value$158.19
Share Statistics
Q32 Bio has 29,764,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding29,764,000
Owned by Insiders6.63%
Owned by Institutions1.02%
Financial Efficiency
Q32 Bio’s return on equity (ROE) is 0.71 and return on invested capital (ROIC) is 29.47%.
Return on Equity (ROE)0.71
Return on Assets (ROA)0.48
Return on Invested Capital (ROIC)29.47%
Return on Capital Employed (ROCE)0.34
Revenue Per Employee2.44M
Profits Per Employee1.36M
Employee Count22
Asset Turnover0.87
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Q32 Bio is 5.8. Q32 Bio’s PEG ratio is -0.00932.
PE Ratio5.8
PS Ratio0.76
PB Ratio0.97
Price to Fair Value0.97
Price to FCF-1.22
Price to Operating Cash Flow-12.13
PEG Ratio-0.00932
Income Statement
In the last 12 months, Q32 Bio had revenue of 53.74M and earned 29.82M in profits. Earnings per share was 2.42.
Revenue53.74M
Gross Profit53.74M
Operating Income16.90M
Pretax Income29.82M
Net Income29.82M
EBITDA31.31M
Earnings Per Share (EPS)2.42
Cash Flow
In the last 12 months, operating cash flow was -26.17M and capital expenditures 0.00, giving a free cash flow of -26.17M billion.
Operating Cash Flow-26.17M
Free Cash Flow-26.17M
Free Cash Flow per Share-0.88
Dividends & Yields
Q32 Bio pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.33
52-Week Price Change771.51%
50-Day Moving Average13.87
200-Day Moving Average6.77
Relative Strength Index (RSI)53.31
Average Volume (3m)1.83M
Important Dates
Q32 Bio upcoming earnings date is Nov 5, 2026, After Close (Confirmed).
Last Earnings DateAug 5, 2026
Next Earnings DateNov 5, 2026
Ex-Dividend Date―
Financial Position
Q32 Bio as a current ratio of 4.85, with Debt / Equity ratio of 4.31%
Current Ratio4.85
Quick Ratio4.85
Debt to Market Cap0.25
Net Debt to EBITDA-1.05
Interest Coverage Ratio15.37
Taxes
In the past 12 months, Q32 Bio has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Q32 Bio EV to EBITDA ratio is 0.25, with an EV/FCF ratio of -0.24.
EV to Sales0.15
EV to EBITDA0.25
EV to Free Cash Flow-0.24
EV to Operating Cash Flow-0.24
Balance Sheet
Q32 Bio has $106.27M in cash and marketable securities with $4.56M in debt, giving a net cash position of $101.71M billion.
Cash & Marketable Securities$106.27M
Total Debt$4.56M
Net Cash$101.71M
Net Cash Per Share$3.42
Tangible Book Value Per Share$3.42
Margins
Gross margin is 100.00%, with operating margin of 31.45%, and net profit margin of 55.49%.
Gross Margin100.00%
Operating Margin31.45%
Pretax Margin55.49%
Net Profit Margin55.49%
EBITDA Margin58.27%
EBIT Margin57.54%
Analyst Forecast
The average price target for Q32 Bio is $42.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$42.75
Price Target Upside182.18% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast―
EPS Growth Forecast―